Danish pharma giant Novo Nordisk entered a deal to acquire small biotech Ziylo, gaining access to its next-generation glucose-sensitive insulins for diabetes. The deal signed on 17 August could be worth more than $800 million for the Bristol, UK-based startup if all milestones are met. Read more in Nature Biotechnology.
diabetes
George King: research leader at the Joslin Diabetes Center
Like many medical researchers, George King has a personal connection to the disease that he has spent his career studying. He has been working to understand and treat diabetes at the Joslin Diabetes Center in Boston, MA, USA, since 1981, partly because of how it has affected his own family. “Asians develop diabetes at a […]
Profile: Joslin Diabetes Center, Boston, MA, USA
The Joslin Diabetes Center has a long history of being on the cutting edge of diabetes care and research. It was founded 117 years ago by Elliott Joslin, a physician dedicated to understanding and treating type 1 diabetes in young people. He used the latest methods to treat the disease—which at that time mainly meant […]
Gut microbe may fight obesity and diabetes
Bacterium helps to regulate metabolism in mice. The gut is home to innumerable different bacteria — a complex ecosystem that has an active role in a variety of bodily functions. In a study published this week in Proceedings of the National Academy of Sciences, a team of researchers finds that in mice, just one of those […]